1 research outputs found
High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation : a report of the Polish Myeloma Study Group
The present retrospective analysis evaluated the
efficacy and safety of the VTD (bortezomib, thalidomide,
dexamethasone) regimen in 205 newly‑diagnosed patients with
multiple myeloma (MM) eligible for high dose therapy and
autologous stem cell transplantation (HDT/ASCT) in routine
clinical practice. With a median of 6 cycles (range, 1‑8), at least partial response was achieved in 94.6% and at least very good
partial response (VGPR) was achieved in 67.8% of patients.
Peripheral neuropathy (PN) grade 2‑4 was observed in 28.7% of
patients. In 72% of patients undergoing stem cell mobilization
one apheresis allowed the number of stem cells sufficient for
transplantation to be obtained. Following HDT/ASCT the sCR
rate increased from 4.9 to 14.4% and CR from 27.8 to 35.6%.
The results demonstrated that VTD as an induction regimen
was highly efficient in transplant eligible patients with MM
with increased at least VGPR rate following prolonged treatment
(≥6 cycles). Therapy exhibited no negative impact on stem
cell collection, neutrophils and platelets engraftment following
ASCT. Therapy was generally well tolerated and PN was the
most common reason of dose reduction or treatment discontinuation